Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director comp.
Senti Biosciences, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
08/11/2023 8-K Quarterly results
08/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/10/2023 8-K Asset disposition
Docs: "Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners – Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies –"
05/09/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/09/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Senti Bio Announces First Quarter 2023 Results and Pipeline Updates – New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy&#59; remains on track for IND submission and clearance in 2H 2023 –"
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/22/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/22/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Quarterly results
Docs: "Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights - SENTI-202 on track to submit an Investigational New Drug application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS -"
02/14/2023 SC 13G PRICE T ROWE ASSOCIATES INC reports a 8.1% stake in Senti Biosciences Inc
02/14/2023 SC 13G/A Sculptor Capital LP reports a 0% stake in SENTI BIOSCIENCES INC
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/13/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A MORGAN STANLEY reports a 0.6% stake in Senti Biosciences, Inc.
02/08/2023 SC 13G Lonsdale Joe reports a 5.8% stake in Senti Biosciences, Inc.
02/02/2023 4 Lee Philip J (Chief Technology Officer) has filed a Form 4 on Senti Biosciences, Inc.
Txns: Granted 195,000 options to buy @ $1.81, valued at $353k
02/02/2023 4 KNOBELMAN DEBORAH (CFO) has filed a Form 4 on Senti Biosciences, Inc.
Txns: Granted 130,000 options to buy @ $1.81, valued at $235.3k
02/02/2023 4 Rajangam Kanya (Chief Medical & Devt. Officer) has filed a Form 4 on Senti Biosciences, Inc.
Txns: Granted 130,000 options to buy @ $1.81, valued at $235.3k
02/02/2023 4 Lu Timothy K (CEO and President) has filed a Form 4 on Senti Biosciences, Inc.
Txns: Granted 630,000 options to buy @ $1.81, valued at $1.1M
01/27/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
01/27/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy